{"abstract": "Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside.", "web_url": "https://www.nytimes.com/2015/11/20/business/dealbook/high-risk-and-low-benefit-in-pfizers-pursuit-of-allergan.html", "snippet": "Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside.", "lead_paragraph": "Pfizer\u2019s $150 billion Botox gamble is a high-risk, low-benefit deal.", "source": "The New York Times", "multimedia": [], "headline": {"main": "High Risk and Low Benefit in Pfizer\u2019s Pursuit of Allergan", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 4, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 5, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 6, "major": "N"}], "pub_date": "2015-11-19T19:12:32+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/09141cb3-72e2-5666-a4f6-4d41be980422", "word_count": 389, "uri": "nyt://article/09141cb3-72e2-5666-a4f6-4d41be980422"}